Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduction of FR900525 using an S-(2-aminoethyl) l-cysteine-resistant mutant.

Journal of bioscience and bioengineering - 1 Jun 2017

Shimizu Shiho, Futase Ayako, Yokoyama Tatsuya, Ueda Satoshi, Honda Hiroyuki

Abstract excerpt

FK506 (tacrolimus), a macrolide compound with immunosuppressant activity, has been proven to have clinical importance and has been manufactured industrially since 1993 by using mutants with high FK506-production ability; these mutants have been developed from the wild strain Streptomyces tsukubaensis No. 9993. FR900525 is one of the by-products of FK506 production. However, there was no effective industrial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cysteine
Share to Mutation
Share to Oxidation-Reduction

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Streptomyces

Share to Tacrolimus

Share to Ultraviolet Rays

Source

Identifiers

PMID: 28185832
DOI: 10.1016/j.jbiosc.2017.01.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduction of FR900525 using an S-(2-aminoethyl) l-cysteine-resistant mutant.PMID 28185832Read ↗

Improvement of FK506 production via metabolic engineering-guided combinational strategies in Streptomyces tsukubaensisSemantic proximity Read ↗

Enhancement of FK520 production in Streptomyces hygroscopicus var. ascomyceticus ATCC 14891 by overpressing the pathyway specific regulatory gene fkbR2Semantic proximity Read ↗

FK506 biosynthesis is regulated by two positive regulatory elements in Streptomyces tsukubaensisSemantic proximity Read ↗

Combination of Atmospheric and Room Temperature Plasma (ARTP) mutagenesis, Genome shuffling and Dimethyl sulfoxide (DMSO) feeding to improve FK506 production in Streptomyces tsukubaensisSemantic proximity Read ↗

Roles of fkbN in positive regulation and tcs7 in negative regulation of FK506 biosynthesis in Streptomyces sp. strain KCTC 11604BP.Semantic proximity Read ↗

Mutational biosynthesis of tacrolimus analogues by fkbO deletion mutant of Streptomyces sp. KCTC 11604BP.Semantic proximity Read ↗

Draft Genome of Streptomyces tsukubaensis NRRL 18488, the Producer of the Clinically Important Immunosuppressant Tacrolimus (FK506)Semantic proximity Read ↗

Optimization of FK-506 production in Streptomyces tsukubaensis by modulation of Crp-mediated regulationSemantic proximity Read ↗

Enhanced FK506 production in Streptomyces tsukubaensis by rational feeding strategies based on comparative metabolic profiling analysisSemantic proximity Read ↗

Improvement of FK506 Production in Streptomyces tsukubaensis by Genetic Enhancement of the Supply of Unusual Polyketide Extender Units via Utilization of Two Distinct Site-Specific Recombination SystemsSemantic proximity Read ↗

Enhanced ε-poly-L-lysine production by inducing double antibiotic-resistant mutations in Streptomyces albulus.Semantic proximity Read ↗

Enhancement of FK506 production by engineering secondary pathways of <i>Streptomyces tsukubaensis</i> and exogenous feeding strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.